98 related articles for article (PubMed ID: 32203769)
1. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
Sherman S; Rotem O; Shochat T; Zer A; Moore A; Dudnik E
Lung Cancer; 2020 May; 143():40-46. PubMed ID: 32203769
[TBL] [Abstract][Full Text] [Related]
2. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.
Dudnik E; Kareff S; Moskovitz M; Kim C; Liu SV; Lobachov A; Gottfried T; Urban D; Zer A; Rotem O; Onn A; Wollner M; Bar J;
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597218
[TBL] [Abstract][Full Text] [Related]
3. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study.
Tong L; Wan Y; Shi X; Liu X; Liu Z; Li Y; Zhang Y; Luo D; Zhu J
Cancer Control; 2024; 31():10732748241253959. PubMed ID: 38736182
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
Iida Y; Wakuda K; Kenmotsu H; Doshita K; Kodama H; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Ko R; Ono A; Naito T; Murakami H; Sugino T; Gon Y; Takahashi T
Sci Rep; 2024 Apr; 14(1):7641. PubMed ID: 38561461
[TBL] [Abstract][Full Text] [Related]
5. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Schmid S; Mauti LA; Friedlaender A; Blum V; Rothschild SI; Bouchaab H; Frösch P; Britschgi C; König D; Wannesson L; Janthur WD; Schär S; Demmer I; Addeo A; Jochum W; Früh M
Cancer Immunol Immunother; 2020 Aug; 69(8):1605-1613. PubMed ID: 32307579
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].
Chen YQ; Zhang YD; Yan H; Qin HY; Huang Z; Zhang X; Xiang SQ; Hu XQ; Wu F; Zhang YC; Zeng L; Yang N
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):282-289. PubMed ID: 38246773
[No Abstract] [Full Text] [Related]
7. Metformin use and lung cancer survival: a population-based study in Norway.
Brancher S; Støer NC; Weiderpass E; Damhuis RAM; Johannesen TB; Botteri E; Strand TE
Br J Cancer; 2021 Mar; 124(5):1018-1025. PubMed ID: 33262518
[TBL] [Abstract][Full Text] [Related]
8. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
Naidoo J; Santos-Zabala ML; Iyriboz T; Woo KM; Sima CS; Fiore JJ; Kris MG; Riely GJ; Lito P; Iqbal A; Veach S; Smith-Marrone S; Sarkaria IS; Krug LM; Rudin CM; Travis WD; Rekhtman N; Pietanza MC
Clin Lung Cancer; 2016 Sep; 17(5):e121-e129. PubMed ID: 26898325
[TBL] [Abstract][Full Text] [Related]
9. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study.
Thuillier P; Joly C; Alavi Z; Crouzeix G; Descourt R; Quere G; Kerlan V; Roudaut N
Cancer Immunol Immunother; 2021 Jul; 70(7):2023-2033. PubMed ID: 33423089
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center.
Popov P; Steindl A; Wolff L; Bergen ES; Eckert F; Frischer JM; Widhalm G; Fuereder T; Raderer M; Berghoff AS; Preusser M; Kiesewetter B
Clin Exp Metastasis; 2024 Feb; 41(1):25-32. PubMed ID: 38064128
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
Yokota E; Iwai M; Yukawa T; Naomoto Y; Haisa M; Monobe Y; Takigawa N; Fukazawa T; Yamatsuji T
Cancer Lett; 2024 Apr; 588():216816. PubMed ID: 38499265
[TBL] [Abstract][Full Text] [Related]
12. The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China.
Wang Z; Wu Y; Lu T; Xu Y; Chen M; Zhong W; Zhao J; Wang M
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38180312
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Patients with Large-Cell Neuroendocrine Carcinoma of the Lung.
Çırak AK; Ceylan KC; Varol Y; Karadeniz G; Aydoğdu Z; Acar A; Balcı G; Kömürcüoğlu B; Mertoğlu A; Öndeş Z; Tekgül S; Vayısoğlu G; Yalnız E
Turk Thorac J; 2020 May; 21(3):150-155. PubMed ID: 32584230
[TBL] [Abstract][Full Text] [Related]
14. Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience.
Eldessouki I; Gaber O; Namad T; Wang J; Morris JC; Abdel Karim N
J Oncol; 2018; 2018():9761826. PubMed ID: 30515212
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy.
Jin S; Shen Z; Li J; Liu X; Zhu Q; Li F; Shi Y; Lin P; Xu X; Chen X; Geng X; Ding X; Liu H
J Clin Pathol; 2024 Jan; ():. PubMed ID: 38242556
[TBL] [Abstract][Full Text] [Related]
16. Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab.
Oda R; Okuda K; Yamashita Y; Sakane T; Tatematsu T; Yokota K; Endo K; Nakanishi R
Thorac Cancer; 2020 Jul; 11(7):2036-2039. PubMed ID: 32379390
[TBL] [Abstract][Full Text] [Related]
17. Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report.
Takimoto Sato M; Ikezawa Y; Sato M; Suzuki A; Kawai Y
Mol Clin Oncol; 2020 Jul; 13(1):43-47. PubMed ID: 32499913
[TBL] [Abstract][Full Text] [Related]
18. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts.
Lantuejoul S; Fernandez-Cuesta L; Damiola F; Girard N; McLeer A
Transl Lung Cancer Res; 2020 Oct; 9(5):2233-2244. PubMed ID: 33209646
[TBL] [Abstract][Full Text] [Related]
19. PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Arpin D; Charpentier MC; Bernardi M; Monnet I; Boni A; Watkin E; Goubin-Versini I; Lamy R; Gérinière L; Geier M; Forest F; Gervais R; Madrosyk A; Guisier F; Serrand C; Locher C; Decroisette C; Fournel P; Auliac JB; Jeanfaivre T; Letreut J; Doubre H; Francois G; Piton N; Chouaïd C; Damotte D
Ther Adv Med Oncol; 2020; 12():1758835920937972. PubMed ID: 32684990
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
